ACTN4 and melanoma: Finally, we investigated the therapeutic efficacy mRNA vaccine encoding neoantigens of PDZ-binding kinase (PBK) and actinin alpha 4 (ACTN4), which were identified from the B16F10 murine melanoma mutanomes (26).